DOI:
10.1055/s-00034922
Arthritis und Rheuma
LinksClose Window
References
Ruperto N, Quartier P, Wulffraat N. et al.
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features.
Arthritis and rheumatism 2012;
64 (02) 557-567.
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.